دورية أكاديمية
[Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis].
| العنوان: | [Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis]. |
|---|---|
| المؤلفون: | Smirnova AG, Smirnov AV, Zander A, Afanas'ev BV |
| المصدر: | Terapevticheskii arkhiv [Ter Arkh] 2010; Vol. 82 (10), pp. 61-4. |
| نوع المنشور: | Clinical Trial; English Abstract; Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Print Cited Medium: Print ISSN: 0040-3660 (Print) Linking ISSN: 00403660 NLM ISO Abbreviation: Ter Arkh Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2018- > : Moskva : ZAO 'Konsilium Medikum' Original Publication: Moskva : Izdatelʹstvo Medit︠s︡ina |
| مواضيع طبية MeSH: | Amyloidosis/*therapy , Dexamethasone/*therapeutic use , Hematopoietic Stem Cell Transplantation/*methods , Melphalan/*therapeutic use , Peripheral Blood Stem Cell Transplantation/*methods, Adult ; Aged ; Amyloidosis/diagnosis ; Amyloidosis/drug therapy ; Amyloidosis/mortality ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Drug Therapy, Combination ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Middle Aged ; Peripheral Blood Stem Cell Transplantation/adverse effects ; Transplantation, Autologous |
| مستخلص: | Aim: To evaluate the efficiency of chemotherapy with standard doses of melfalan and dexamethazone versus autologous peripheral hemopoietic cell transplantation (auto-PHCT) in patients with AL amyloidosis and to reveal poor prognostic factors. Subjects and Methods: Of 36 patients diagnosed as having AL-amylodosis, 17 patients underwent auto-PHCT, 11 patients received chemotherapy only; 8 patients died prior to treatment. Results: In patients with AL-amyloidosis after chemotherapy and autotransplantation, 3-year overall survival was 28 and 64%, respectively. Low somatic ECOG status and cardiac lesion were independent poor prognostic factors of the disease. The number of involved organs failed to affect overall survival. Conclusion: Auto-PHCT may be proposed as first-line therapy for patients with AL-amyloidosis who have a somatic ECOG score of 0 to 2 and not more than 3 organs involved. Young patients who have a satisfactory somatic status and no benefit from autotransplantation may undergo auto-PHCT. It is expedient to use average-dose melfalan and dexamethasone when treating patients who are ineligible for high-dose chemotherapy. |
| المشرفين على المادة: | 7S5I7G3JQL (Dexamethasone) Q41OR9510P (Melphalan) |
| تواريخ الأحداث: | Date Created: 20110224 Date Completed: 20110404 Latest Revision: 20131121 |
| رمز التحديث: | 20221213 |
| PMID: | 21341467 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0040-3660 |
|---|